Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
193,828,463
-
Total 13F shares
-
100,520,271
-
Share change
-
+3,913,138
-
Total reported value
-
$3,523,336,508
-
Price per share
-
$35.05
-
Number of holders
-
85
-
Value change
-
+$149,163,509
-
Number of buys
-
57
-
Number of sells
-
25
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q4 2019
As of 31 Dec 2019,
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
100,520,271 shares.
The largest 10 holders included
Kohlberg Kravis Roberts & Co. L.P., VIKING GLOBAL INVESTORS LP, AMERICAN INTERNATIONAL GROUP INC, HILLHOUSE CAPITAL ADVISORS, LTD., Aisling Capital Management LP, JANUS HENDERSON GROUP PLC, BlackRock Inc., SC US (TTGP), LTD., Cormorant Asset Management, LP, and FMR LLC.
This page lists
85
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.